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A case of flecainide toxicity in a young male
Ifrah Butt, Umair Shaikh, Marlena Fernandez, Sameer Shaharyar, Daniel Heller MD
Introduction:
Flecainide is an antiarrhythmic drug with a narrow therapeutic window. It is a powerful sodium channel
blocker that can be used to treat various types of supraventricular tachycardias. However, due to its
narrow therapeutic window, there is potential for a fatal overdose. Flecainide overdose is a rare
phenomenon with only a few case reports and their subsequent clinical outcome published. We present
a case of a 24-year old male who presented with cardiac arrest after an intentional ingestion of large
quantities of flecainide. Our goal is to raise awareness for characteristic signs and symptoms, highlight
therapeutic options and discuss the pathophysiology of the overdose.
Case description:
A 24-year-old male with a known history of schizophrenia was brought in to the emergency room by
ambulance after being found unresponsive at home. Family members noted that he was
vomiting, seizing and was found unresponsive 20 minutes later. Emergency medical services were called
and by the time they arrived, he had been unresponsive for about 40 minutes. Given the clinical picture
and psychiatric history, there was a high index of suspicion for overdose. Eventually, an empty bottle of
flecainide was recovered by the family. Initial electrocardiogram (EKG) in the emergency room revealed
an undetermined rhythm with wide and varying QRS complexes, as well as a prolonged QTc at 650
ms. Soon after arrival, the patient went into cardiopulmonary arrest and cardiopulmonary resuscitation
(CPR) was started per Advanced Cardiac Life Support protocol. The initial rhythm was pulseless electrical
activity arrest. Return of spontaneous circulation was achieved after 2 cycles of CPR. The rhythm postarrest was wide complex bradycardia. The patient was hemodynamically unstable with low blood
pressure. The decision was made to undergo synchronized cardioversion with conversion to a wide
complex rhythm with marginal improvement in blood pressure. Norepinephrine infusion was initiated to
sustain adequate cerebral perfusion pressures. Initial arterial blood gas demonstrated a severe mixed
respiratory and metabolic acidosis. The patient was hyperventilated in order to correct the underlying
respiratory acidosis and on advice from local poison control center he was started on a sodium
bicarbonate drip to be titrated to the normalization of the QTc interval. Electrolytes were monitored
and replenished as needed. Intralipid bolus was given in an attempt to ameliorate the effects of druginduced cardiotoxicity. Targeted temperature management was initiated due to unresponsiveness postarrest.
In the Intensive Care Unit, the patient was found to have a profoundly resistant acidemia requiring well
over 750 mEq of sodium carbonate over the next 24 hours. Serial EKGs were done (below) which
demonstrated gradual normalization of the QTc interval after serum alkalinization. Serum flecainide
levels were obtained on the second day of admission and were elevated at 1.31 microgram/ml
(reference range 0.2-1.00). During targeted temperature management the patient developed (narrow
complex) bradycardia which corrected with a dopamine infusion. After rewarming, the patient was
unresponsive, with brain imaging revealing the diffuse global hypoxic injury. The patient subsequently
underwent tracheostomy and percutaneous endoscopic gastrostomy tube placement and was
transferred out of the ICU.

Discussion:
Flecainide, a class IC antiarrhythmic, causes rate-dependent slowing of sodium channels (citation). In
therapeutic doses, this effect will lead to membrane stabilization and decreased conduction velocity of
the His-Purkinje and ventricular systems with the therapeutic goal of achieving and maintaining sinus
rhythm [11]. However, in higher doses, flecainide may lead to inhibition of calcium-induced calcium
secretion from the sarcoplasmic reticulum during phase 2 of the cardiac action potential [11]. This
process is thought to be mediated by the blockage of the ryanodine receptor [12]. Thus, flecainide
overdose may be clinically apparent in an EKG which would demonstrate an increase in PR interval, QRS
complex, and QTc prolongation [13](additional citation).
In our patient, several EKGs were performed that demonstrated abnormalities consistent with flecainide
toxicity. The first EKG in Figure 1 (Initial EKG) demonstrated a QRS > .200 ms, severely prolonged QTc,
loss of P waves, heart rate of 100, and borderline extreme axis deviation. A systematic review of
flecainide toxicity and corresponding EKG findings demonstrated that there doesn’t appear to be a
relationship between the amount of flecainide consumed and QRS duration or associated features
(valentino). However, the degree of widening of the QRS complex is rate-dependent, increasing as the
heart rate increases (andri). In Figure 2 (EKG @ 18:30), a rate-dependent decrease of the QRS to .160 ms
is demonstrated with an associated heart rate in the 70s.
Drug overdose has an overall mortality of <1%, however, overdose with class IC antiarrhythmics was
associated with higher mortality rates at 22.5% [1]. Though the therapeutic implications of flecainide are
well known, prior to initiating treatment clinicians should evaluate for contraindications such as
structural heart disease, AV block, left bundle branch block, right bundle branch block (when associated
with left hemiblock), asymptomatic nonsustained ventricular tachycardia, cardiogenic shock, reduced
cardiac output (LVEF < 35%), post-MI, and significant renal or hepatic impairment [4]. Flecainide
metabolism and excretion is mediated by the liver and kidney respectively (andri). Significant
impairment of either organ system should be evaluated prior to initiation. After initiation of flecainide,
use-dependent QRS widening may be assessed during a formal exercise test. As previously mentioned,
the QRS width is directly related to the heart rate and an increase in heart rate (via exercise) should
mediate a corresponding increase in the width of the QRS complex. During treatment, the QRS interval
should be regularly monitored[7](additional citation).
Flecainide is known to have a narrow therapeutic index, with a peak plasma time 2-3 hrs (PO)
and therapeutic range 0.2-1mcg/mL. Oral administration of flecainide results in extensive absorption
(bioavailability of 90–95%). Flecainide does not appear to undergo significant hepatic first-pass
metabolism; a 200–500 mg daily dose produced plasma concentrations within the therapeutic range of
200–1000 µg/L (the maximum daily dose is 300 mg) [5,6]. The elimination half-life is 12–27 h [5].
Flecainide undergoes extensive hepatic biotransformation via cytochrome P450 CYP2D6; inactive
metabolites are excreted mostly (85%) in urine and excretion increases with low urine pH. Some
metabolites are excreted via feces. There are also increased serum levels in renal impairment. Total
plasma clearance 10 mL/min/kg.
Treatment of flecainide overdose requires a high level of suspicion and appropriate clinical history.
However, even with optimal management, overdose carries a significant mortality rate. Several options
are available that have been studied for the management of flecainide toxicity. Standard treatment
involves aggressive electrolyte correction, fluid resuscitation and addressing conduction abnormalities.
Determining the onset of ingestion has significant implications. If the patient presents within one hour

gastric lavage or activated charcoal are acceptable options for rapid decontamination and minimize the
amount of circulating medication[3].
The use of sodium bicarbonate infusion serves two important functions. Firstly, the increase in sodium
concentration displaces flecainide from its receptor sites on cardiac myocytes. Secondly, sodium
bicarbonate causes alkalinization of the serum which causes a reduction in the degree of sodium
channel blockade. There is support for sodium bicarbonate infusion to a goal of pH 7.50 to 7.55 when
the QRS duration is greater than 160ms [8]. However, the one caveat is hypothetically alkalinization of
urine increases elimination half-life and decreases the overall urinary clearance of flecainide (citation).
Local poison control suggested initiating infusion of intravenous fat emulsion (IFE). The mechanism of
action of IFE is unclear, however, it is postulated that it follows the mechanisms of the “lipid-sink
theory” whereby IFE acts to sequester lipophilic drugs such as flecainide, thereby reducing toxic activity
on cardiac myocytes [9]. If the hemodynamic compromise is persistent and severe, consideration is
given to extracorporeal membrane oxygenation (ECMO). ECMO provides respiratory and more
importantly cardiac support, preventing end-organ damage such as renal dysfunction which is integral to
the elimination of the drug. The length of the ECMO support may be determined by serum flecainide
level and cardiac stability [10]. Finally, flecainide is a dialyzable medication which gives it a
consideration for treatment in overdose, particularly in patients with renal impairment.
Conclusion:
Flecainide toxicity is a rarely encountered, but potentially lethal presentation that can lead to
life-threatening arrhythmias. It is important to identify and begin treatment early with sodium
bicarbonate, EKG monitoring, IFE infusion, and consideration for dialysis or ECMO to promote renal
clearance.
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